Reports Q3 revenue $0, consensus $130,000. “With the U.S. Food and Drug Administration having approved AUCATZYL for the treatment of adult B-cell Acute Lymphoblastic Leukemia patients, we are all systems go with our commercial efforts in the US across the Company,” said Dr. Christian Itin, Chief Executive Officer of Autolus. “This first FDA approval is just the beginning for Autolus; we have great belief in our pipeline and our manufacturing capabilities and are excited for the future.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AUTL:
- Is AUTL a Buy, Before Earnings?
- Autolus Therapeutics announces FDA approval of Aucatzyl
- FDA approves obecabtagene autoleucel for certain type of ALL
- Autolus Therapeutics to present clinical data updates at ASH 2024
- Autolus Therapeutics presents clinical data on obe-cel treatment
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
